The effect of antibiotics on the clinical outcomes of patients with solid cancers undergoing immune checkpoint inhibitor treatment: a retrospective study

Hyunho Kim¹, Ji Eun Lee², Sook Hee Hong², Myung Ah. Lee², Jin Hyoung Kang² and In-Ho Kim²,3*

Abstract

Background: This study aimed to assess the effect of antibiotics on the clinical outcomes of patients with solid cancers undergoing treatment with immune checkpoint inhibitors (ICIs).

Methods: The medical records of 234 patients treated with ICIs for any type of solid cancer between February 2012 and May 2018 at the Seoul St. Mary's Hospital were retrospectively reviewed. The data of patients who received antibiotics within 60 days before the initiation of ICI treatment were analyzed. The patients' responses to ICI treatment and their survival were evaluated.

Results: Non-small-cell lung carcinoma was the most common type of cancer. About half of the patients were treated with nivolumab (51.9%), and cephalosporin (35.2%) was the most commonly used class of antibiotics. The total objective response rate was 21%. Antibiotics use was associated with a decreased objective response (odds ratio 0.466, 95% confidence interval [CI] 0.225–0.968, p = 0.040). The antibiotics group exhibited shorter progression-free survival (PFS) and overall survival (OS) than the no antibiotics group (median PFS: 2 months vs. 4 months, p < 0.001; median OS: 5 months vs. 17 months, p < 0.001). In the multivariate analysis, antibiotics use was a significant predictor of patient survival (PFS: hazard ratio [HR] 1.715, 95% CI 1.264–2.326, p = 0.001; OS: HR 1.785, 95% CI 1.265–2.519, p = 0.001).

Conclusions: The use of antibiotics may affect the clinical outcomes of patients with solid cancers treated with ICIs. Careful prescription of antibiotics is warranted in candidates who are scheduled for ICI treatment.

Trial registration: Not applicable (retrospective study).

Keywords: Immunotherapy, Antibiotics, Survival, Solid cancer, Immune checkpoint inhibitors, Gut microbiota, Retrospective study, Korea

Background

The success of ipilimumab, which is an anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) monoclonal antibody (mAb), in the treatment of advanced melanoma started a new era of immune checkpoint inhibitors (ICIs) in systemic anti-cancer treatment [1]. After ipilimumab, the anti-programmed cell death protein-1 (PD-1) mAb was developed as novel ICI; it is now widely used to treat various metastatic cancers and has shown improved survival [2, 3]. Although ICI therapy has been shown to be associated with longer survival and an extended duration of the treatment response in patients with solid cancers [4, 5], not all such patients benefit from ICIs [1–5]. Only about 20% of patients treated with ICI show long-term survival of up to 10 years, and some develop severe immune-related side effects resulting in harmful outcomes such as pneumonitis, myocarditis, or hepatitis [5–7]. Therefore, many studies on the selection of candidates for ICI treatment are being conducted
worldwide. For example, it has been reported that programmed death ligand-1 (PD-L1) expression and the tumor mutation burden are predictive biomarkers for improved patient outcomes [8].

ICIs targeting the PD-1/PD-L1 axis are the most widely used ICIs in the treatment of solid cancers [2, 3, 9]. PD1/PD-L1 binding inhibits stimulatory signaling of T-cell receptors, thereby reducing their proliferation, inflammatory cytokine production, and survival [9]. Anti-PD-1 and PD-L1 mAbs restore the T-cell-mediated immune response against cancer cells by preventing PD1/PD-L1 binding. Similarly, the CTLA-4 mAb restores the T-cell-mediated anticancer immune reaction by competing with cluster of differentiation 28 (CD28) binding B7, a costimulatory molecule [9]. Considering that ICIs act on T-cell immunity, we hypothesized that antibiotics use may affect the efficacy of ICI treatment in patients with solid cancers due to the association between antibiotics and the gut microbiota. Antibiotics are commonly used in clinical practice, including in the treatment of patients with cancer. They change the composition of the gut microbiota, modulating the host immune response through the development and education of the immune system [10, 11]. Unlike the 1990s, when 60–80% of intestinal bacteria were undetectable in culture tests [12], the recent development of multi-omics techniques has allowed for a more comprehensive analysis of gut microbiota composition through deep 16S rRNA sequencing [12–15]. Using this methodology, preclinical studies showed that the use of antibiotics can change T-cell immunity by altering the gut microbiota [10–12]. This study aimed to investigate the effect of antibiotics use on the clinical outcomes of patients with solid cancers receiving ICI treatment.

Methods
Study population
This retrospective study was approved by the Institutional Review Board (IRB) of the Seoul St. Mary’s Hospital of the Catholic University of Korea (KC19RESI0114). The need for informed consent was waived by the IRB of the Seoul St. Mary’s Hospital of the Catholic University of Korea due to the retrospective study design.

The medical records of patients treated with ICIs (anti-PD-1, anti-PD-L1, and anti CTLA-4 mAbs) for any type of solid cancer at the hospital between February 2012 and May 2018 were reviewed. Patients who died within 4 weeks of antibiotics administration were excluded as they either had a very poor performance status or did not recover from a severe infection. The treatment regimens included ICI alone, ICI combination therapy, and ICI plus chemotherapy, regardless of previous anticancer treatment.

Variables and outcomes
The clinicopathologic characteristics of all patients were assessed. Medical records were reviewed after classifying the patients according to the timing of antibiotics administration (no antibiotics, antibiotics use within 30 days of ICI treatment initiation, and antibiotics use 31–60 days before ICI treatment initiation). Previous studies showed that alterations in the gut microbiota occurred in less than 1 week after treatment initiation and lasted for 1–3 months up to 2 years [16–18]. Considering the estimated minimum recovery time of the gut microbiota, most patients treated with antibiotics within 1 to 2 months before the start of ICI treatments will not have a recovered gut microbiota.

We analyzed the presence of bacteremia (indicating severe systemic infection), when antibiotics treatment was initiated, the type of antibiotics used, the route of administration, and the treatment duration. As the study population was highly heterogeneous, we also performed a subgroup analysis of patients with non-small-cell lung carcinoma (NSCLC) as this was the most common type of cancer identified in this study. In patients with NSCLC, PD-L1 expression, the presence of an epidermal growth factor receptor (EGFR) mutation, and the histological subtype were also assessed.

To evaluate the treatment response, we reviewed the results of imaging studies including computed tomography and magnetic resonance imaging. Radiological changes were evaluated using the Response Evaluation Criteria for Solid Tumors, version 1.1 [19]. An objective response was categorized as a complete response (CR) or partial response (PR), while disease control was categorized as CR, PR, or stable disease (SD). All patients were followed up until death or data lock (January 10, 2019).

Statistical analysis
Patients were categorized according to the status of antibiotic use (yes vs. no) within 60 days prior to the start of ICI treatment. The patients’ baseline characteristics were compared using the Chi-squared or Fisher’s exact test for categorical variables. Survival curves were calculated using the Kaplan-Meier method, and the log-rank test was used to compare the survival curves. A Cox proportional hazards model was used to perform a multivariate analysis to assess prognostic variables for progression-free survival (PFS) and overall survival (OS). The Chi-squared test was employed to determine differences in the overall response between the antibiotics and no antibiotics groups; several therapeutic
| Table 1 Baseline characteristics (N = 234) |
|------------------------------------------|

|                      | Total (%) | No Antibiotics (%) | Antibiotics (%) | \( \rho \) value |
|----------------------|-----------|--------------------|-----------------|------------------|
| **Age**              |           |                    |                 |                  |
| < 65                 | 110 (47)  | 56 (44.4)          | 54 (50)         | 0.396            |
| ≥ 65                 | 124 (53)  | 70 (55.6)          | 54 (50)         |                  |
| **Sex**              |           |                    |                 |                  |
| Male                 | 168 (71.8)| 91 (72.2)          | 77 (71.8)       | 0.875            |
| Female               | 66 (28.2) | 35 (27.8)          | 31 (28.2)       |                  |
| **ECOG score**       |           |                    |                 |                  |
| 0–1                  | 200 (87.7)| 112 (92.6)         | 88 (82.2)       | 0.018            |
| 2–3                  | 28 (12.3) | 9 (7.4)            | 19 (17.8)       |                  |
| unknown              | 6         | 5                  | 1               |                  |
| **Diagnosis**        |           |                    |                 |                  |
| NSCLC                | 131 (56)  | 71 (56.3)          | 48 (55.6)       | 0.903            |
| Others\(^a\)         | 103 (44)  | 55 (43.7)          | 60 (44.4)       |                  |
| **Stage**            |           |                    |                 |                  |
| III                  | 9 (3.8)   | 6 (4.8)            | 3 (2.8)         | 0.511            |
| IV                   | 225 (96.2)| 120 (95.2)         | 105 (97.2)      |                  |
| **Number of metastatic organ** |      |                    |                 |                  |
| 0 or 1               | 151 (64.5)| 78 (61.9)          | 73 (67.6)       | 0.365            |
| ≥ 2                  | 83 (35.5) | 48 (38.1)          | 35 (32.4)       |                  |
| **Number of treatment line** |    |                    |                 |                  |
| 1st                  | 72 (30.8) | 45 (35.7)          | 27 (25)         | 0.198            |
| 2nd                  | 96 (41)   | 49 (38.9)          | 47 (43.5)       |                  |
| ≥ 3rd                | 66 (28.2) | 32 (25.4)          | 34 (31.5)       |                  |
| **ICI**              |           |                    |                 |                  |
| Nivolumab            | 135 (57.7)| 79 (62.7)          | 56 (51.9)       | 0.242            |
| Pembrolizumab        | 62 (26.5) | 29 (23)            | 33 (30.6)       |                  |
| Others\(^b\)         | 37 (15.8) | 18 (14.3)          | 19 (17.6)       |                  |
| **Treatment combination** |      |                    |                 |                  |
| ICI alone            | 189 (80.8)| 97 (77)            | 92 (85.2)       | 0.063            |
| ICI with ICI         | 20 (8.5)  | 10 (7.9)           | 10 (9.3)        |                  |
| ICI with chemotherapy| 25 (10.7)| 19 (15.1)          | 6 (5.6)         |                  |
| **Clinical trial**   |           |                    |                 |                  |
| Yes                  | 108 (46.2)| 72 (57.1)          | 36 (33.3)       | < 0.001          |
| No                   | 126 (53.8)| 54 (42.9)          | 72 (66.7)       |                  |
| **Antibiotics type** |           |                    |                 |                  |
| No Antibiotics       | 126 (53.8)| 126                |                 |                  |
| Antibiotics          | 108 (46.2)| Cephalosporins     | 38 (35.2)       |                  |
|                       |           | Fluoroquinolones   | 26 (24.1)       |                  |
|                       |           | Beta-lactam/Betalactamase inhibitors | 18 (16.6) |         |
|                       |           | Others\(^c\)      | 26 (24.1)       |                  |

\(^a\)Melanoma, N = 27; Bladder, N = 8; Renal cell carcinoma, N = 9; Head and Neck cancer, N = 16; Stomach cancer, N = 21; Hepato cellular carcinoma, N = 7; Esophageal cancer, N = 5; Small cell lung cancer, N = 3; Anal cancer, Cervical cancer, Colorectal cancer, Jejunal cancer, MUCO, Ovarian cancer, Sarcoma, N = 1, respecitively

\(^b\)Avelumab, N = 9; Durvalumab, N = 5; Atezolizumab, N = 4; Ipilimumab, N = 15

\(^c\)Carbapenem, Glycopeptides, Macrolides and etc
windows were evaluated (no antibiotics, antibiotics use within 30 days of ICI treatment initiation, and antibiotics use 31–60 days before ICI treatment initiation). The same analyses were performed in the NSCLC subgroup.

All statistical analyses were performed using the SPSS software (version 24; IBM corp., Armonk, NY, USA). A two-sided \(p\)-value < 0.05 was considered significant.

**Results**

**Baseline characteristics of the patients**

A total of 234 patients were included in the study. Table 1 shows the patients’ characteristics by antibiotic use. NSCLC was the most common type of cancer. The most common treatment regimen used was ICI alone (\(N = 189\), 80.8%). ICI combination therapy (\(N = 20\), 8.5%) consisted mostly of nivolumab with ipilimumab. Of all patients, 108 (46.2%) received antibiotics at least once within 60 days prior to the initiation of ICI treatment. Cephalosporin was the most commonly used antibiotic (\(N = 38\), 35.2%), followed by quinolone (\(N = 26\), 24.1%). Oral antibiotics were more commonly prescribed than intravenous antibiotics (62% vs. 38%). Most patients received antibiotics for prophylactic use (\(N = 79\), 73.1%); accordingly, only 26.9% of the patients (\(N = 29\)) were administered for treatment. Anti-fungal agents were used in only one patient who was treated with oral fluconazole due to oral candidiasis. The antibiotics group had a higher proportion of patients with a high Eastern Cooperative Oncology Group performance status (ECOG PS) of 2–3.

**Survival and response to treatment**

The patients’ responses to treatment are described in Fig. 1 and Table 2. None of the patients achieved a CR. The total objective response rate was 21%. A history of antibiotics use was associated with a decreased objective response (odds ratio [OR] 0.466, 95% confidence interval [CI] 0.225–0.968; \(p = 0.040\)) and decreased disease control (OR 0.517, 95% CI 0.294–0.910; \(p = 0.022\)). The antibiotics group showed shorter PFS and OS than the no antibiotics group (median PFS: 2 months vs. 4 months, \(p < 0.001\); median OS: 5 months vs. 17 months, \(p < 0.001\) (Fig. 2).

![Fig. 1 Immune checkpoint inhibitors; treatment response in solid cancer](image)

**Table 2** Immune checkpoint inhibitors, Treatment response in solid cancer

|        | Total | ATB | no ATB | \(p\) value | Total | ATB | no ATB | \(p\) value |
|--------|-------|-----|--------|-------------|-------|-----|--------|-------------|
| CR     | 44 (21%) | 12 (14%) | 32 (26%) | 0.034 OR 44 (21%) | 12 (14%) | 32 (26%) | 0.038 |
| PR     | 83 (39.5%) | 32 (37%) | 51 (41%) | nOR 166 (79%) | 74 (86%) | 92 (74%) | |
| SD     | 83 (39.5%) | 42 (49%) | 41 (33%) | DC 127 (60%) | 44 (51%) | 83 (67%) | 0.022 |
| PD     | Total 210 | 86 | 124 | nDC 83 (40%) | 42 (49%) | 41 (33%) | |

Non-evaluated, \(N = 24\)

ATB Antibiotics
In the univariate analysis, antibiotics use within 60 days before the initiation of ICI treatment, the ECOG PS, the number of metastatic organs, cancer stage, previous chemotherapy, combination therapy, participation in a clinical trial, and antibiotics administration during ICI treatment affected both OS and PFS (Table 3). In the multivariate analysis, a history of antibiotics use within 60 days prior to the start of ICI therapy was significantly associated with survival (PFS: hazard ratio [HR] 1.715, 95% CI 1.264–2.326, \( p = 0.001 \); OS: HR 1.785, 95% CI 1.265–2.519, \( p = 0.001 \)) (Table 3).

We then classified the study population into patients who received no antibiotics, those who received antibiotics within 30 days before ICI therapy initiation, and those who received antibiotics 31–60 days before ICI therapy and conducted the same analyses. A history of antibiotics use negatively affected the treatment response (rate of progressive disease [PD]: none vs. 30 days vs. 60 days: 33.1% vs. 43.6% vs. 53.2%; \( p = 0.013 \)) (Additional file 1). Patients receiving antibiotics had shorter PFS and OS than those not receiving antibiotics (none vs. 30 days vs. 60 days: median PFS: 4 months vs. 1 months vs. 2 months, \( p < 0.001 \); median OS: 17 months vs. 4 months vs. 7 months, \( p < 0.001 \)) (Additional file 2). In the multivariate analysis, a history of antibiotics use was an independent prognostic factor (PFS, \( p = 0.002 \); OS, \( p < 0.001 \)) (Additional file 3).

**NSCLC subgroup: survival and objective response**

The baseline characteristics of the NSCLC subgroup are shown in Table 4. Of all patients, 131 (56%) had NSCLC; of these, 60 (45.8%) received antibiotics within 60 days prior to ICI therapy initiation. The most common class of antibiotics was cephalosporin; oral antibiotics were more frequently prescribed than intravenous antibiotics. We found similar rates of brain metastasis, previous chemotherapy, the histologic type of NSCLC, PD-L1 expression, and the presence of an EGFR mutation in the antibiotics and no antibiotics group. The antibiotics group had higher proportions of patients with an ECOG PS of 2–3 and those enrolled in clinical trials when compared to the no antibiotics group.

A history of antibiotics use was associated with a higher rate of PD (antibiotics vs. no antibiotics: 50% vs. 22.5%, \( p = 0.006 \)) and a decreased treatment response; however, there was no statistically significant difference in the objective response rate between the two groups (antibiotics vs. no antibiotics: objective response rate: 16% vs. 29.6%, \( p = 0.085 \); disease control rate: 50% vs. 77.5%, \( p = 0.002 \)) (Fig. 3 and Table 5). The antibiotics group exhibited shorter PFS and OS than the no antibiotics group (median PFS: 2 months vs. 7 months, \( p < 0.001 \); median OS: 4 months vs. 22 months, \( p < 0.001 \)) (Fig. 4). The multivariate analysis revealed that a history of antibiotics use, the ECOG PS, cancer stage, number of metastatic organs, brain metastasis, participation in a clinical trial, PD-L1 expression, and the presence of an EGFR mutation were independent predictors of survival (PFS: HR 2.379, 95% CI 1.281–4.418, \( p = 0.006 \); OS: HR 3.834, 95% CI 1.736–8.469, \( p = 0.001 \)) (Table 6). Both PFS and OS were significantly different between patients not receiving antibiotics and those who underwent antibiotics treatment.
within 30 days or within 31–60 days prior to ICI therapy initiation (no antibiotics vs. 30 days vs. 31–60 days: median PFS: 7 months vs. 1 month vs. 2 months; median OS: 22 months vs. 4 months vs. 8 months; p = 0.001). In the NSCLC group, patients treated with a BLBLI showed trends of longer PFS and OS when compared to those treated with other types of antibiotics (cephalosporins vs. quinolones vs. BLBLI vs. others: median PFS: 1 months vs. 1 months vs. 8 months vs. 2 months; median OS: 3 months vs. 4 months vs. 9 months vs. 7 months); however, the differences were not statistically significant.

All nine patients in the NSCLC subgroup treated with a BLBLI received antibiotics via the intravenous route. We hypothesized that the route of antibiotics administration may affect survival. However, there was no significant difference in survival between patients receiving oral agents and those receiving intravenous agents (PFS: p = 0.232; OS: p = 0.531). Moreover, the administration of antibiotics during ICI therapy was not associated with survival (PFS: p = 0.084; OS: p = 0.845).

### Table 3 Multivariate analysis

|                | PFS    | OS     |
|----------------|--------|--------|
|                | Multivariate | Multivariate |
|                | HR     | 95% CI | p value |
|                | HR     | 95% CI | p value |
| ECOG           |        |        |         |
| 0 or 1         | 0.003  | < 0.001|
| 2 or 3         | 1.907  | 1.245–2.921 | 2.607  | 1.666–4.080 |
| Diagnosis      |        |        |         |
| NSCLC          | 0.062  |        |
| Others*        | 1.328  | 0.986–1.788 |
| Stage          |        |        |         |
| III            | 0.025  | 0.103  |
| IV             | 2.605  | 1.130–6.004 | 2.332  | 0.842–6.461 |
| Number of metastatic organ |        |        |
| 0 or 1         |        |        |         |
| ≥ 2            | 1.6    | 1.135–2.256 |
| Number of treatment line |        |        |
| 1st            | < 0.001 |        |
| 2nd            | 2.035  | 1.410–2.939 | < 0.001 |
| ≥ 3rd          | 1.885  | 1.269–2.800 | 0.002  |
| Clinical trial |        |        |         |
| Yes            | 1.829  | 1.266–2.641 |
| No             | 0.037  |        |
| Antibiotics during ICI |        |        |
| No             |        | 0.7    | 0.501–0.978 |
| Yes            | 1.715  | 1.264–2.326 | 1.785  | 1.265–2.519 |

*Melanoma, Bladder cancer, Renal cell carcinoma, Head and Neck cancer, Stomach cancer, Hepato cellular carcinoma, Esophageal cancer, Small cell lung cancer, Anal cancer, Cervical cancer, Colorectal cancer, Jejunal cancer, MUC, Ovarian cancer, Sarcoma

#### Discussion

In this study, we analyzed the effect of antibiotics use on clinical outcomes in patients with solid cancers undergoing treatment with ICIs. Almost half of the patients (46.2%) received antibiotics prior to the start of ICI therapy. A history of antibiotics use showed a significant association with ICI treatment outcomes and survival; similar results were seen in the NSCLC subgroup.

When interpreting our results, several issues should be considered. First, patients treated with antibiotics had a poorer general condition (as measured by the ECOG PS) when compared to those not receiving antibiotics. The proportion of patients with an ECOG PS of 2–3 was significantly lower in the no antibiotics group than in the antibiotics groups (7.4% vs. 17.8%). As expected, we found a significant difference in median OS between the low and high ECOG PS subgroups (11 months vs. 2 months, p < 0.001). However, the total proportion of
| Table 4 Baseline characteristics in NSCLC (N = 131) |
|---------------------------------|-----------------|-----------------|-----------------|-----------------|
|                                  | Total (%)       | No Antibiotics (%) | Antibiotics (%) | p value         |
| Age                             |                 |                  |                 |                 |
| < 65                            | 56 (42.7)       | 28 (39.4)        | 28 (46.7)       | 0.405           |
| ≥ 65                            | 75 (57.3)       | 43 (60.6)        | 32 (53.3)       |                 |
| Sex                             |                 |                  |                 |                 |
| Male                            | 99 (75.6)       | 54 (76.1)        | 45 (75)         | 0.889           |
| Female                          | 32 (24.4)       | 17 (23.9)        | 15 (25)         |                 |
| ECOG                            |                 |                  |                 |                 |
| 0–1                             | 116 (89.9)      | 66 (95.7)        | 50 (83.3)       | 0.02            |
| 2–3                             | 13 (10.1)       | 3 (4.3)          | 10 (16.7)       |                 |
| Unknown                         | 2               | 2                | 0               |                 |
| Stage                           |                 |                  |                 |                 |
| III                             | 4 (3.1)         | 3 (4.2)          | 1 (1.7)         | 0.625           |
| IV                              | 127 (96.9)      | 68 (95.8)        | 59 (98.3)       |                 |
| Number of metastatic organ      |                 |                  |                 |                 |
| 0 or 1                          | 85 (64.9)       | 47 (66.2)        | 38 (63.3)       | 0.732           |
| ≥ 2                             | 46 (35.1)       | 24 (33.8)        | 22 (36.7)       |                 |
| Brain metastasis                |                 |                  |                 |                 |
| No                              | 106 (80.9)      | 57 (80.3)        | 49 (81.7)       | 0.841           |
| Yes                             | 25 (19.1)       | 14 (19.7)        | 11 (18.3)       |                 |
| Number of treatment line        |                 |                  |                 |                 |
| 1st                             | 39 (29.8)       | 25 (35.2)        | 14 (23.3)       | 0.204           |
| 2nd                             | 56 (42.7)       | 29 (40.8)        | 27 (45)         |                 |
| ≥ 3rd                           | 36 (27.5)       | 17 (23.9)        | 19 (31.7)       |                 |
| ICI                             |                 |                  |                 |                 |
| Nivolumab                       | 71 (54.2)       | 44 (62)          | 27 (45)         | 0.024           |
| Pembrolizumab                   | 41 (31.3)       | 15 (21.1)        | 26 (43.3)       |                 |
| Othersa                         | 19 (14.5)       | 12 (16.9)        | 7 (11.7)        |                 |
| Treatment combination           |                 |                  |                 |                 |
| ICI alone                       | 104 (79.4)      | 53 (74.6)        | 51 (85)         | 0.117           |
| ICI with ICI                    | 7 (5.3)         | 3 (4.2)          | 4 (6.7)         |                 |
| ICI with chemotherapy           | 20 (15.3)       | 15 (21.1)        | 5 (8.3)         |                 |
| Clinical trial                  |                 |                  |                 |                 |
| Yes                             | 65 (49.6)       | 46 (64.8)        | 19 (31.7)       | < 0.001         |
| No                              | 66 (50.4)       | 25 (35.2)        | 41 (68.3)       |                 |
| Histologic subtype              |                 |                  |                 |                 |
| Adenocarcinoma                  | 83 (63.4)       | 46 (64.8)        | 37 (61.7)       |                 |
| Squamous cell carcinoma         | 44 (33.6)       | 24 (33.8)        | 20 (33.3)       |                 |
| Othersb                         | 4 (3.1)         | 1 (1.4)          | 3 (5)           |                 |
| PD-L1                            |                 |                  |                 |                 |
| Negative                        | 14 (13.6)       | 11 (20.4)        | 3 (6.1)         | 0.058           |
| Low                             | 30 (29.1)       | 17 (31.5)        | 13 (26.5)       |                 |
| High                            | 59 (57.3)       | 26 (48.1)        | 33 (67.3)       |                 |
| Unknown                         | 28               | 17               | 11              |                 |
| EGFR                            |                 |                  |                 |                 |
patients with an ECOG PS of 2–3 was small at 11.9% (specifically, only 4 patients [1.7%] had an ECOG PS of 3); thus, the majority of patients analyzed had a good performance status. Moreover, the shapes of the ECOG PS survival curves were different between the antibiotics groups at the end of the curves (Additional file 6). In the multivariate analysis, when controlling for the ECOG PS, a history of antibiotics use was an independent prognostic factor. Furthermore, the most common reason for antibiotics use was prophylaxis (79 patients, 73.1%) which was defined as the response to an elevated C-reactive protein level only (without fever or specific localized symptoms); bacteremia was observed in only 4 of 108 patients (3.7%) who were treated with antibiotics. In other words, we presume that severe systemic infection and a poor performance status had a limited effect on the association between antibiotics use and ICI treatment-related outcomes in this study, although the ECOG PS is a well-known prognostic factor.

Our data revealed a higher rate of PD and lower objective response rate in the antibiotics group than in the non-antibiotics group (PD: 49% vs. 33%; objective response rate: 18% vs. 26%). Meanwhile, the antibiotics group had shorter PFS than the no antibiotics group (2

---

**Table 4** Baseline characteristics in NSCLC \((N = 131)\) (Continued)

|                           | Total (%) | No Antibiotics (%) | Antibiotics (%) | \(p\) value |
|---------------------------|-----------|--------------------|----------------|-------------|
| Negative                  | 92 (88.5) | 53 (89.8)          | 39 (86.7)      | 0.617       |
| Positive                  | 12 (11.5) | 6 (10.2)           | 6 (13.3)       |             |
| Unknown                   | 27        | 12                 | 15             |             |
| Antibiotics type          |           |                    |                |             |
| No Antibiotics            | 71 (54.2) |                   |                |             |
| Antibiotics               | 60 (45.8) | Cephalosporins     | 17 (28.3)      |             |
|                           |           | Fluoroquinolones   | 16 (26.7)      |             |
|                           |           | Beta-lactam/Betalactamase inhibitors | 9 (15) |             |
|                           |           | Others\(^c\)      | 18 (30)        |             |
| Administration Route      |           |                    |                |             |
| Oral                      | 37        |                   | 37 (61.7)      |             |
| Intravenous               | 23        |                   | 23 (38.3)      |             |

\(^a\)Avelumab, \(N = 6\); Durvalumab, \(N = 5\); Ipilimumab, \(N = 8\)
\(^b\)Sarcomatoid carcinoma, \(N = 2\), Large cell neuroendocrine carcinoma, \(N = 1\); Poorly differentiated carcinoma, \(N = 1\)
\(^c\)Carbapenem, Glycopeptides, Macrolides and etc.

**Fig. 3** Immune checkpoint inhibitors; treatment response in NSCLC.
months vs. 4 months). These findings suggest that the use of antibiotics can have a negative effect on the efficacy of ICI treatment. Previous studies support the possibility that antibiotics administration affects the clinical efficacy of ICI [16, 20]. Derosa et al. reported an increased risk of PD (75% vs. 22%, \( p < 0.01 \)) as well as shorter PFS and OS in patients with renal cell carcinoma or NSCLC treated with antibiotics [16]. Similarly, Ahmed et al. showed that patients with various types of solid cancers receiving broad-spectrum antibiotics had a lower response rate (25% vs. 61%, \( p = 0.02 \)) and shorter PFS than those not receiving antibiotics [20]. These data indicate that changes in the intestinal flora due to the effects of antibiotics may be one of the causes of the poor efficacy of ICI.

Trillions of bacteria live along the gastrointestinal tract [11]. Under normal conditions, the host immune system maintains beneficial strains and prevents the overproliferation and rapid growth of non-beneficial strains [10]. Exposure to antibiotics can impair the homeostasis of gut microbiota, resulting in decreased microbial diversity (the variability of harmful and healthy bacteria) [12]. Previous studies reported that cephalosporins and BLBLI, which were the most common antibiotics used in this study, modulated the composition of Firmicutes, Bacteroidetes, and Proteobacteria in the intestinal-bacterial community [12, 21]. Fluoroquinolone was also shown to play an important role in modulating the gut microbiota, with the degree of alterations differing according to the category of quinolones used [12, 22]. The disruption of the gut microbiota affects systemic T-cell activity and their number, along with an impairment of dendritic cell migration, immunoglobulin levels, and interferon-gamma levels [10]. Abt et al. showed that exposure to antibiotics was associated with a reduced expansion of lymphocytic choriomeningitis virus (LCMV)-specific CD8+ T cells in mice, releasing effector molecules such as interleukin-2 and interferon-gamma [23]. Considering these previous studies, a well-designed prospective study using stool samples is needed to confirm how antibiotics change the gut microbiota, ultimately causing altered ICI efficacy.

### Table 5 Immune checkpoint inhibitors, Treatment response in NSCLC

|       | Total | ATB | no ATB | \( p \) value | Total | ATB | no ATB | \( p \) value |
|-------|-------|-----|--------|--------------|-------|-----|--------|--------------|
| CR    | 0     | 0   | 0      | 0.006        | 0     | 0   | 0      | 0.085        |
| PR    | 29 (24%) | 8 (16%) | 21 (30%) |            | 92 (76%) | 42 (84%) | 50 (70%) |             |
| SD    | 51 (42%) | 17 (34%) | 34 (48%) |            | 80 (66%) | 25 (50%) | 55 (78%) | 0.002        |
| PD    | 41 (34%) | 25 (50%) | 16 (22%) |            | 41 (34%) | 25 (50%) | 16 (22%) |            |
| Total | 121   | 50  | 71     |              | 121   | 50  | 71     |              |

Non-evaluated, \( N = 10 \)

ATB: Antibiotics

![Fig. 4 Survival curves and the impact of antibiotics in NSCLC patients treated with ICIs. ATB: antibiotics](image-url)
The type of antibiotics, route of administration, and duration of antibiotics treatment were not associated with treatment outcomes in our study. Arboleya et al. reported that beta-lactams and BLBLI reduced the proportion of *Actinobacteria*, including *Bifidobacterium*, in preterm infants [24]. In another study,
ciprofloxacin was associated with a decreased proportion of *Bifidobacterium* [11, 25]. Although previous studies reported that both BLBLI and ciprofloxacin decreased intraluminal *Bifidobacterium*, the specific strain linked to the efficacy of ICI and how the type of antibiotics affects the clinical outcomes of patients treated with ICIs remain unclear. We considered that the intra-luminal concentration of antibiotics differs according to the route of administration. Our findings showed that the ratio between oral and intravenous antibiotic use was highly unbalanced. For example, fluoroquinolones, including ciprofloxacin with a bioavailability of about 70% in the oral route [26], was orally administered in only 1% of the 26 patients. Thus, we could not adequately compare oral and intravenous use. In terms of the period of antibiotics use, the most common antibiotics treatment duration was ≥7 days (82 patients, 76%). Short-term antibiotics use can also affect the gut microbiota [11, 17], and our study population included patients who received antibiotics for <7 days. Unlike the use of antibiotics before ICI therapy, antibiotics use during ICI therapy did not affect survival in this study. This may be because ICI not only reactivates cytotoxic T cells but also modulates memory T cells [27]. Modified T-cell immunity caused by the first administration of ICI may persist thereafter and Survival may therefore not be significantly affected by antibiotics use during ICI therapy.

This study had some limitations. As discussed earlier, a higher proportion of patients treated with antibiotics had a poor performance status when compared to those who did not receive antibiotics; the ECOG PS is an important prognostic factor in itself. ICI treatment can be continued beyond progression as long as patients show no significant deterioration, which can affect the evaluation of progression. Thus, caution must be exercised when interpreting our data. Second, the study design was a retrospective review of medical records. Therefore, we could not perform culture testing of the patients’ stool samples and utilize multi-omics technologies to confirm gut microbiota alterations according to antibiotics administration. Accordingly, we were unable to analyze if differences in the gut microbiota affected ICI treatment outcomes. In a previous study, an abundance of *Akkermansia muciniphila* was correlated with the anti-PD-1 immunotherapy response in patients who underwent a stool metagenomics analysis prior to treatment [28]. Sivan et al. reported that the oral administration of *Bifidobacterium* enhanced the response of anti-PD-1 therapy in mice with melanoma [29]. Vetizou et al. showed that *Bacteroides* species modulated the efficacy of anti-CTLA-4 therapy in mice treated with antibiotics [30]. Considering these and our findings, fecal microbiota transplantation (FMT) may ameliorate ICI treatment outcomes in patients with solid cancers. Routy et al. showed that FMT from ICI responders into germ-free or antibiotic-treated mice improved the tumor control of anti PD-1 mAbs, whereas FMT from non-responders was unable to achieve tumor control [28]. Oral administration of *A. muciniphila* with FMT of non-responder feces restored the antitumor effect of anti-PD-1 mAb through the accumulation of CCR9+ CXCR3+ CD4+ T lymphocytes in mouse tumor beds [28]. Third, our study population was heterogeneous as it consisted of patients who underwent treatment for various cancer types. According to the type of cancer, cancer biology and treatment course are different. Therefore, a study in patients with a homogeneous cancer type is ideal. However, the sample size of this study was small; therefore, we had to evaluate all patients treated with ICIs, irrespective of the type of cancer. Last, this study was designed without controlling for host factors related to the gut microbiota such as lifestyle and the neonatal environment [12]. Hence, further studies in homogeneous patient groups are needed.

**Conclusion**

The findings of our study suggest that the use of antibiotics may affect the clinical outcomes of patients with solid cancers treated with ICI. Prescribing antibiotics only as needed and considering the potential misuse of antibiotics may improve treatment outcomes in individuals who are scheduled to receive ICI treatment.

**Supplementary information**

Supplementary information accompanies this paper at https://doi.org/10.1186/s12885-019-6267-z.

**Additional file 1.** Immune check point inhibitors, Treatment response in solid cancer. Non-evaluated, N = 24, ATB 60: antibiotics use within 60 days before ICI start, ATB 30: antibiotics use within 30 days before ICI start.

**Additional file 2.** Survival curves and the impact of antibiotics in solid cancer patients treated with ICIs. ATB 60: antibiotic use within 60 days prior to ICI treatment, ATB 30: antibiotic use within 30 days prior to ICI treatment.

**Additional file 3.** Multivariate analysis.

**Additional file 4.** Survival curves and the impact of antibiotics in NSCLC patients treated with ICIs. ATB 60: antibiotic use within 60 days prior to ICI treatment, ATB 30: antibiotic use within 30 days prior to ICI treatment.

**Additional file 5.** Survival curves and the impact of antibiotics administration in less than 7 days in solid cancer patients treated with ICI. ATB: antibiotics.

**Additional file 6.** Comparing between survival curves depending on ECOG and antibiotics. ATB: antibiotics, ECOG: Eastern Cooperative Oncology Group score.

**Abbreviations**

BLBLI: Beta-lactam/beta-lactamase inhibitor; CD28: Cluster of differentiation 28; CI: Confidence interval; CR: Complete response; CTLA-4: Cytotoxic T-lymphocyte associated protein 4; ECOG PS: Eastern Cooperative Oncology
Group Performance Status; EGFR: Epidermal growth factor receptor; FMT: Fecal microbiota transplantation; HR: Hazard ratio; ICI: Immune checkpoint inhibitor; IRB: Institutional Review Board; LOMV: Lymphocytic choriomeningitis virus; mAb: Monoclonal antibody; NSCLC: Non-small-cell lung carcinoma; OR: Odds ratio; PD: Progressive disease; PD-1: Programmed cell death protein-1; PDL-1: Programmed death-ligand 1; PR: Partial response; SD: Stable disease

Acknowledgements
Not applicable.

Authors' contributions
KH collected and analyzed all patient data and was a major contributor in writing the manuscript. LJE analyzed and interpreted the patient data on sarcoid. HSH analyzed and interpreted the patient data on NSCLC and gynecologic cancer. LMA analyzed and interpreted the patient data on colorectal cancer and hepatocellular carcinoma. KIH analyzed and interpreted the patient data on gastric cancer, esophageal cancer, and genitourinary cancer; moreover, KI-H was a major contributor to the interpretation of all data. All authors read and approved the final manuscript.

Funding
This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (No. NRF-2018R1C1B6008724). This funding was used for proofreading English. There was not any role of the NRF in the design of this study and collection, analysis, and interpretation of the data.

Availability of data and materials
The data that support the findings of this study are available from the corresponding author but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the corresponding author upon reasonable request and with permission of the Institutional Review Board of the Seoul St. Mary's Hospital.

Ethics approval and consent to participate
This retrospective study was approved by the IRB of the Seoul St. Mary's Hospital of the Catholic University of Korea (KC19RES0114). The need for informed consent was waived by the IRB of the Seoul St. Mary's Hospital of the Catholic University of Korea due to the study design as this was a retrospective review of medical records.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Division of Medical Oncology, Department of Internal Medicine, The Catholic University of Korea, St. Vincent's Hospital, Suwon, Republic of Korea.
2Division of Medical Oncology, Department of Internal Medicine, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Republic of Korea.
3Department of Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, 222 Banpo-daero, Seocho-gu, Seoul 137-701, Korea.

Received: 11 May 2019 Accepted: 15 October 2019
Published online: 12 November 2019

References
1. Hodi FS, O'Day SJ, McDermott DF, Weir:JW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorff D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:879–86.
2. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al. Nivolumab versus Docetaxel in advanced nonsquamous non-small-cell lung Cancer. N Engl J Med. 2015;373(7):1627–39.
3. Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Cruszo T, Fulop A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung Cancer. N Engl J Med. 2016;375(19):1823–33.
4. Schadendorff D, Hodi FS, Robert C, Weber JS, Margolin K, Harald R, Battist D, Chen TT, Berman DM, Wolchok JD. Pooled analysis of Long-term survival data from phase II and phase III trials of ipilimumab in Unresectable or metastatic melanoma. J Clin Oncol. 2015;33(17):1889–94.
5. McDermott D, Lebbe C, Hodi FS, Maio M, Weber JS, Wolchok JD, Thompson JA. Balch CM. Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. Cancer Treat Rev. 2014;40(9):1059–64.
6. Fuentes-Atmar J, Provencio M, Diaz-Rubio E. Hyperprogression as a distinct outcome after immunotherapy. Cancer Treat Rev. 2018;70:16–21.
7. Puzanov I, Diab A, Abdallah K, Bingham CO 3rd, Brodgon C, Dadu R, Hamad L, Kim S, Lacouture ME, LeBoeuf NR, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) toxicity management working group. J Immunother Cancer. 2017;5(1):99.
8. Clark DP. Biomarkers for immune checkpoint inhibitors: the importance of tumor topography and the challenges to cytopathology. Cancer Cytopathol. 2018;126(1):11–9.
9. Buchbinder E, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol. 2016;39(1):98–106.
10. Becattini S, Taur Y, Parner EG. Antibiotic-induced changes in the intestinal microbiota and disease. Trends Mol Med. 2016;22(8):458–78.
11. Iizumi T, Battaglia T, Ruiz V, Perez Perez GJ. Gut microbiome and antibiotics. Arch Med Res. 2017;48(8):727–34.
12. Ianiro G, Tilg H, Gasbarrini A. Antibiotics as deep modifiers of gut microbiota: between good and evil. Gut. 2016;65(1):1905–16.
13. Pérez-Cobas AE, Gosales MJ, Friedrichs A, Knecht H, Antacho A, Eismann K, Otto W, Rojo D, Bargiela R, von Bergen M. Gut microbiota disturbance during antibiotic therapy: a multi-omic approach. Gut. 2015;64(11):1591–601.
14. Dethlefsen L, Huse S, Sogin ML, Relman DA. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol. 2008;6(11):e280.
15. Francino MP. Antibiotics and the human gut microbiome: Dysbioses and accumulation of resistances. Front Microbiol. 2015;6:1543.
16. Derosa L, Hellmann MD, Spaziano M, Halpenny D, Fidelle M, Rizvi H, Long N, Plokoviski AJ, Arbour KC, Wilt EA, et al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann Oncol. 2018;29(6):1437–44.
17. Jernberg C, Löfmark S, Edlund C, Jansson JK. Long-term ecological impacts of antibiotic administration on the human intestinal microbiota. ISME J. 2007;1(1):56.
18. Lange K, Buerger M, Stallmach A, Bruns T. Effects of antibiotics on gut microbiota. Dig Dis. 2016;34(3):260–8.
19. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.
20. Ahmed J, Kumar A, Parkih K, Anvar A, Knoll BM, Puccio C, Chun H, Fanucchi M, Lim SH. Use of broad-spectrum antibiotics as biomarkers of immune checkpoint inhibitors in patients treated with immune checkpoint inhibitors. Oncocimmunology. 2018;7(11):e1507670.
21. Knecht H, Neuling SC, Heinzen FA, Knecht C, Schillhaber A, Schmitz RA, Zimmerman A, dos Santos VM, Ferrer M, Rosenstiel PC. Effects of β-lactam antibiotics and fluoroquinolones on human gut microbiota in relation to Clostridium difficile associated diarrhea. PLoS One. 2014;9(2):e89417.
22. Inagaki Y, Nakaya R, Chida T, Hashimoto T. The effect of levofloxacin, an optically-active isomer of ofloxacin, on fecal microflora in human volunteers. Jpn J Antibiot. 1992;45(3):241–7.
23. Zimmermann A, dos Santos VM, Ferrer M, Rosenstiel PC. Effects of levofloxacin on fecal microflora in human volunteers. Jpn J Antibiot. 2000;53(9):707–13.
24. Arboleya S, Sanchez B, Solis G, Fernandez N, Suarez M, Hernandez-Barranco AM, Milani C, Margolles A, de los Reyes-Gavilan CG, Ventura M, et al. Impact of Prematurity and Perinatal Antibiotics on the Developing Intestinal Microbiota: A Functional Indicator Study. Int J Mol Sci. 2016;17(5):649.
25. Stewardson AJ, Gaia N, Francois P, Malhotra-Kumar S, Delemont C, Martinez de Tejada B, Schrenzel J, Harbarth S, Lazarevic V. Collateral damage from oral ciprofloxacin versus nitrofurantoin in outpatients with urinary tract infections: a culture-free analysis of gut microbiota. Clin Microbiol Infect. 2015;21(4):e341–e344.

26. Turnidge J. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Drugs. 1999;58(2):29–36.

27. Yamaguchi K, Mishima K, Ohmura H, Hanamura F, Ito M, Nakano M, Tsuchihashi K, Ota S, Wada N, Uchi H, et al. Activation of central/effector memory T cells and T-helper 1 polarization in malignant melanoma patients treated with anti-programmed death-1 antibody. Cancer Sci. 2018;109(10):3032–42.

28. Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Dailiere R, Fluckiger A, Messaoudene M, Raurer C, Roberti MP, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359(6371):91–7.

29. Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, Benyamin FW, Lei YM, Jabri B, Alegre ML, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015;350(6264):1084–9.

30. Vetizou M, Pitt JM, Dailiere R, Lepage P, Waldschmitt N, Flament C, Rusakiewicz S, Routy B, Roberti MP, Duong CP, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015;350(6264):1079–84.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.